Secures Interim Approval to Access Debtor-in-Possession Financing Reiterates Commitment to Continue Providing Customers with Unmistakable Value and Extreme Bargains COLUMBUS,…
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at…